Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A minimalist illustration of a lung and a clinical trial document on a solid background.

Jun 4, 2026

Massive Bio, Optellum Partner on Early Detection, Clinical Trial Access for Lung Cancer

Massive Bio and Optellum have joined forces to enhance early detection and clinical trial access for patients with non-small cell lung cancer (NSCLC), addressing a critical gap in cancer care.This partnership aims to bridge the disconnect between high-risk patients identified through routine imaging and their enrollment in clinical trials. Despite lung cancer being the leading cause of cancer-related deaths globally, many high-risk patients never participate in trials, which could significantly
A minimalist illustration of a pill and a medical cross.

Jun 4, 2026

How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors

BridgeBio Pharma has received FDA Priority Review for its New Drug Application for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a target decision date set for November 27, 2026. This marks a significant milestone as BBP-418 could become the first approved therapy for this condition, potentially earning BridgeBio a Priority Review Voucher and enhancing its prospects in the rare disease sector.This Priority Review introduces a pivotal regulatory ca
Silhouette of ginseng and mortar and pestle representing Traditional Chinese Medicine

Jun 4, 2026

AI-Powered TCM Leader: Yineng Pharma Named to Top 100 Innovative Medicine List

Yineng Pharma has achieved a significant milestone by being named to the "Top 100 Innovative Medicine and Biological Products" list at the Future Healthcare 100 Conference held in Shanghai. This recognition underscores the company's advancements in AI-powered Traditional Chinese Medicine (TCM) research and development, positioning it as a leader in the digitization of TCM.The Future Healthcare 100 Conference is a prominent event in China's health sector, attracting over 5,000 professionals, incl
A glass vial with clear liquid on a lab bench in a biotechnology lab

Jun 4, 2026

Alnylam, Inceptive ink AI deal potentially worth $2B

Alnylam Pharmaceuticals has announced a significant collaboration with Inceptive Nucleics, aiming to leverage artificial intelligence (AI) for the accelerated discovery of RNA-based therapies. The initial phase of the partnership includes a $30 million investment, with potential total deal value reaching $2 billion contingent on meeting various milestones.This partnership is a key component of Alnylam's broader "Alnylam 2030" strategy, which focuses on expanding its pipeline of innovative therap
Minimalist illustration of a drug compound

Jun 4, 2026

Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive

Alnylam Pharmaceuticals has initiated a significant collaboration with Inceptive, aiming to leverage generative AI to enhance its RNA interference (RNAi) drug discovery efforts. This partnership is strategically aligned with Alnylam's objectives for its Alnylam 2030 pipeline expansion, focusing on accelerating the development of innovative RNAi therapeutics. Inceptive's AI platform is designed to identify complex biological patterns and apply them across various therapeutic contexts without the
A minimalist representation of a molecular structure in a dark color scheme.

Jun 4, 2026

Pfizer to Leverage Chai Discovery’s AI Platform

Pfizer has announced a strategic partnership with Chai Discovery to integrate advanced AI capabilities into its drug development processes.This collaboration will allow Pfizer to utilize Chai's AI platform, specifically the Chai-3 model and a customized version that incorporates Pfizer's proprietary data. The aim is to enhance Pfizer's drug discovery engine, streamlining the identification and development of new therapeutic molecules.Chai Discovery specializes in generative AI technology that ca
A DNA sample on a lab bench with a microscope in the background.

Jun 4, 2026

AI Industry Leaders Urge Congress to Regulate Genomic Data Amid New Biotech Partnerships

Leaders in the AI sector are advocating for new regulations on genomic data as the convergence of biotechnology and artificial intelligence intensifies.Prominent figures from leading AI companies are pressing Congress to establish federal regulations to protect DNA data, highlighting the growing intersection of biotechnology and machine learning. This push for regulatory measures comes on the heels of notable partnerships and developments in the industry, including a collaboration between Incept
A transcatheter mitral valve replacement system on a surgical tray in a dimly lit room.

Jun 4, 2026

Rhythm AI appoints medtech veteran Mike Dineen as new CEO

Rhythm AI has appointed Mike Dineen as its new CEO, marking a significant leadership transition for the company as it advances its Star Apollo mapping software.Dineen brings over 30 years of experience in the medtech sector, particularly in cardiovascular technologies. He has a history of guiding innovations from initial development through to market launch and acquisition. Before joining Rhythm AI, he co-founded and led Tioga Cardiovascular, where he worked on a transcatheter mitral valve repla
A tumor sample on a microscope slide in a dimly lit lab

Jun 4, 2026

SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

SOPHiA GENETICS has announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to establish a precision medicine hub aimed at advancing precision oncology.The Memorandum of Understanding (MOU) between SOPHiA GENETICS and MSK seeks to leverage the strengths of both organizations. SOPHiA’s DDM™ platform has analyzed over 2.5 million cases since its inception, while MSK has sequenced more than 150,000 tumor samples, creating a rich dataset that integrates clinical outcome
A minimalist illustration of a syringe and a molecule on a dark background.

Jun 4, 2026

AI Investment Momentum Builds as Enterprises Prioritize High-Impact Use Cases in Q1 2026

In early 2026, enterprise adoption of artificial intelligence is accelerating, driven by a focus on ROI and strategic planning, as highlighted in BCC Research's latest report on AI investment trends.The report indicates that sectors such as technology and consumer electronics are leading in AI spending, reflecting their need for competitive positioning and infrastructure development. Notably, the life sciences and healthcare sectors are also witnessing robust investment, bolstered by strong rese
A clinical data sheet on a desk in a softly lit office

Jun 4, 2026

Century Health Raises $5M Seed Round as AI-Powered Platform Achieves 97% Accuracy in Clinical Data Abstraction

Century Health has successfully raised $5 million in a seed funding round, led by Origin Ventures, to enhance its AI-driven platform, CHARM, which boasts a remarkable 97% accuracy in clinical data abstraction.This funding round included contributions from InnovateHealth Ventures, 25madison, Next Play Ventures, and existing investors like 2048 Ventures and Alumni Ventures. The capital will be allocated towards scaling collaborations with pharmaceutical partners, expanding their provider network,
A drug compound on a laboratory notebook in a research lab

Jun 4, 2026

Meet Dalton, a new AI-powered drug discovery platform

DaltonTx has launched its AI-driven drug discovery platform, Dalton, aimed at streamlining the entire drug development process.The UK-based start-up DaltonTx has officially introduced its platform, Dalton, which is designed to optimize drug discovery from data analysis to molecular design and decision-making. This innovative platform aims to create a "continuous learning engine" that supports both small-molecule and biologic medicines. With a team comprising former scientists from AstraZeneca, E